Related Experiment Video
Updated: Jun 21, 2025
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinoma
Abstract:
Pancreatic ductal adenocarcinoma-(PDAC) needs innovative approaches due to its 12% 5-year survival despite current therapies. We show marked sensitivity of pancreatic cancer cells to the combination of a novel eIF4A inhibitor, des-methyl pateamine A (DMPatA), and a histone deacetylase inhibitor, romidepsin, inducing epigenetic reprogramming as an innovative therapeutic strategy. Exploring the mechanistic activity of this combination showed that with a short duration of romidepsin at low doses, robust acetylation persisted up to 48h with the combination, while histone acetylation rapidly faded with monotherapy. This represents an unexpected mechanism of action against PDAC cells that triggers transcriptional overload, metabolic stress, and augmented DNA damage. Structurally different class I HDAC inhibitors exhibit the same hyperacetylation patterns when co-administered with DMPatA, suggesting a class effect. We show efficacy of this combination regimen against tumor growth in a MIA PaCa-2 xenograft model of PDAC with persistent hyperacetylation confirmed in tumor samples.
Statement Of Significance:
Pancreatic ductal adenocarcinoma, a significant clinical challenge, could benefit from the latent potential of epigenetic therapies like HDAC inhibitors-(HDIs), typically limited to hematological malignancies. Our study shows that a synergistic low dose combination of HDIs with an eIF4A-inhibitor in pancreatic cancer models results in marked pre-clinical efficacy, offering a promising new treatment strategy.
Insights
Pancreatic cancer shows new hope with a combination therapy. Epigenetic reprogramming using histone deacetylase inhibitors and an eIF4A inhibitor demonstrates significant preclinical efficacy against pancreatic ductal adenocarcinoma.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, necessitating novel therapeutic strategies.
- Current treatments for PDAC offer limited survival benefits.
- Epigenetic therapies, particularly histone deacetylase inhibitors (HDACis), show potential but are typically limited to hematological malignancies.
Purpose of the Study:
- To investigate the efficacy of a novel therapeutic strategy combining a histone deacetylase inhibitor (romidepsin) with an eIF4A inhibitor (des-methyl pateamine A, DMPatA) for pancreatic cancer.
- To explore the mechanistic basis of this combination therapy's action in PDAC cells.
- To evaluate the preclinical efficacy of this combination in a PDAC xenograft model.
Main Methods:
- Treatment of pancreatic cancer cells with romidepsin and DMPatA.
- Assessment of histone acetylation patterns and duration.
- Analysis of transcriptional overload, metabolic stress, and DNA damage.
- Evaluation of tumor growth in a MIA PaCa-2 xenograft model.
Main Results:
- The combination of DMPatA and romidepsin induced persistent histone hyperacetylation for up to 48 hours, unlike monotherapy.
- This synergistic effect triggered transcriptional overload, metabolic stress, and increased DNA damage in PDAC cells.
- The combination regimen demonstrated significant efficacy in reducing tumor growth in a PDAC xenograft model.
- Persistent hyperacetylation was confirmed in tumor samples from treated animals.
Conclusions:
- A synergistic low-dose combination of HDAC inhibitors and an eIF4A inhibitor exhibits marked preclinical efficacy in pancreatic cancer models.
- This combination induces epigenetic reprogramming, offering a promising new treatment strategy for pancreatic ductal adenocarcinoma.
- The findings suggest a broader potential for epigenetic therapies in solid tumors like PDAC.
